Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27415031.
- Also identified by DOI 10.1001/jamaoncol.2016.2466.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
What is the optimal platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant neoplasms? Maintaining a higher platelet count threshold (≤20 × 109/L or ≤30 × 109/L) was not associated with less bleeding than the current standard (≤10 × 109/L), but required more platelet transfusions (low-quality evidence).
Medical subject headings
- Antineoplastic Agents
- Hematologic Diseases
- Hematopoietic Stem Cell Transplantation
- Hemorrhage
- Leukemia
- Platelet Transfusion
- Thrombocytopenia